HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a $27 price target.
August 08, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on ACADIA Pharmaceuticals and maintained a $27 price target.
The reiteration of a Buy rating and the maintenance of a $27 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100